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On page 2, [Table 1](#t1-blctt-8-011){ref-type="table"} was incorrectly presented. [Table 1](#t1-blctt-8-011){ref-type="table"} should have been:

###### 

Inhibition of kinases by different TKIs approved for the treatment of CML and/or ALL

  Kinase   Imatinib   Dasatinib   Nilotinib   Bosutinib   Ponatinib
  -------- ---------- ----------- ----------- ----------- -----------
  ABL1     X          X           X           X           X
  T315I               X                       X           X
  FGFR                X                       X           X
  VEGFR                                       X           X
  PDGFR    X          X           X           X           X
  KIT      X          X           X                       X
  FLT3     X                                  X           X
  SRC                 X                       X           X

**Note:** Over 50% inhibition is indicated by X.

**Abbreviations:** ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; TKIs, tyrosine kinase inhibitors; ABL1, abelson murine leukemia viral oncogene homolog 1; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; KIT, stem cell growth factor receptor; FLT3, fms-like tyrosine kinase 3; SRC, sarcoma kinase.
